Sutton Wealth Advisors’s Sage Therapeutics SAGE Stock Holding History

Sutton Wealth Advisors’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-2,979	Closed	-$99.8K	–	1707
2022 Q1	$98.6K	Sell	2,979 -831	-22%	-$31.2K	0.03%	251
2021 Q4	$162K	Hold	3,810	–	–	0.05%	200
2021 Q3	$169K	Hold	3,810	–	–	0.06%	190
2021 Q2	$216K	Hold	3,810	–	–	0.08%	172
2021 Q1	$285K	Hold	3,810	–	–	0.11%	131
2020 Q4	$330K	Hold	3,810	–	–	0.14%	113
2020 Q3	$233K	Hold	3,810	–	–	0.11%	130
2020 Q2	$158K	Buy	3,810 +3,434	+913%	+$125K	0.08%	158
2020 Q1	$10.8K	Buy	+376	New	+$21.8K	0.01%	633
2018 Q3	–	Sell	-63	Closed	-$9.86K	–	1158
2018 Q2	$9.86K	Buy	+63	New	+$9.89K	0.01%	831

Other funds holding SAGE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Sutton Wealth Advisors's SAGE Position: Q2 2022 in Review

Sutton Wealth Advisors sold out of Sage Therapeutics (SAGE) in Q2 2022, closing a stake of 2,979 shares — an estimated $99.8K sold.

Sutton Wealth Advisors first reported a position in SAGE in Q2 2018 and held it in 10 quarters. The position peaked at $330K in Q4 2020. 210 funds tracked by Wall St. Rank hold SAGE as of Q2 2022.

Sutton Wealth Advisors reported no remaining Sage Therapeutics position as of Q2 2022 after selling out during the quarter.
Sutton Wealth Advisors sold 2,979 Sage Therapeutics shares in Q2 2022, an estimated $99.8K.
Sutton Wealth Advisors first reported a position in Sage Therapeutics in Q2 2018 and held it in 10 quarters.
Sutton Wealth Advisors's Sage Therapeutics position peaked at $330K in Q4 2020.
210 funds tracked by Wall St. Rank held Sage Therapeutics as of Q2 2022.

Based on Sutton Wealth Advisors's 13F filing for Q2 2022, filed 7 Nov 2023.